Natasha Dudiki, MD
Critical Care Medicine · Muncie, INNPI 1366859142
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Intuitive Surgical at 52.2% of the total. 2025 is the largest year on record at $2,027, more than ten times the $135 reported in 2021.
Across 126 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AstraZeneca$841
- GSK$684
- Boehringer Ingelheim$123
- Merck$116
- Regeneron Healthcare Solutions, Inc.$87
- plus $336 from 10 others
Across 9 payments — averaging $3386.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$30K
What the payments were for
- Travel & lodging$2,11646%
- Food & beverage$2,44153%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $2,387 |
| AstraZeneca | 38 | $841 |
| GSK | 41 | $684 |
| Boehringer Ingelheim | 1 | $123 |
| Merck | 5 | $116 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Mylan Specialty L.p. | 5 | $75 |
| Viatris Specialty LLC | 3 | $53 |
| Amgen | 3 | $45 |
| Pfizer | 2 | $40 |
| Philips North America LLC | 2 | $33 |
| United Therapeutics Corporation | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,110
- TEZSPIRE$115
How this compares
$4,575 in reported general payments places this provider in the 85th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $397,272 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 485 | $396,521 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $159,906 |
| Breo ElliptaFluticasone/Vilanterol | 253 | $117,601 |
| Dupixent PenDupilumab | 29 | $109,501 |
| XolairOmalizumab | 26 | $88,574 |
| Spiriva RespimatTiotropium Bromide | 93 | $67,284 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $44,987 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 79 | $40,605 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $31,532 |
| Spiriva HandihalerTiotropium Bromide | 25 | $27,724 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $25,017 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $13,741 |
| Roflumilast | 144 | $11,721 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 86 | $10,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $684 | $579,744863 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $123 | $496,088168 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $841 | $58,728101 claims |
| MerckDulera | $116 | $8,73415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Muncie
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
- Laura RodriguezMerrillville$15K
- Ryan BoenteIndianapolis$15K
- Derrick FergusonBloomington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.